Autism Treatment Controversy Grows as Major Clinical Trial Retracted

Retracted Study Sparks Scrutiny of Autism Intervention Claims

The largest clinical trial investigating leucovorin (a prescription form of folate, not an over-the-counter vitamin) as a potential autism intervention was retracted in February 2026 due to flawed methodology, according to The Transmitter. The retraction deals a blow to proponents of the therapy, which had gained traction after being included in federal health initiatives despite limited evidence. Retraction means the study's conclusions are no longer considered valid, but families using leucovorin should consult their doctors before making any changes, as sudden discontinuation may not be advised.

Policy Meets Prescription Trends

A Brown University study published in March 2026 found that a White House autism briefing led to two contradictory trends: decreased use of acetaminophen during pregnancy (amid unproven autism risk concerns) and a 32% increase in off-label (unapproved) leucovorin prescriptions for autistic children over six months. This occurred despite warnings from experts like those at NPR, who noted leucovorin lacks rigorous evidence for autism applications. The therapy was initially explored due to theories about folate metabolism differences in some autistic individuals.

Research Infrastructure Expands Amid Uncertainty

While debates over specific interventions rage, infrastructure for autism studies is growing. UCLA and Children’s Hospital Los Angeles recently secured a $17.25 million NIH grant to join a global autism clinical trials network, signaling continued investment despite methodological challenges. Meanwhile, a Nature study used machine learning to identify potential responders to bumetanide—a drug currently in Phase 3 trials (Mayo Clinic)—highlighting personalized approaches. Autistic self-advocates caution that such research should prioritize quality of life over 'cures,' as noted in the Autism Science Foundation's 2025 review.